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Abstract 
Background: The choice of empirical antimicrobial therapy for pneumonia in intensive care unit (ICU) is a challenge, 
since pneumonia is often related to multidrug‑resistant pathogens, particularly extended‑spectrum β‑lactamase‑
producing Enterobacteriaceae (ESBL‑E). To prevent the overuse of broad‑spectrum antimicrobial therapy, the main 
objective of this study was to test the performance of digestive colonization surveillance as a predictor of ESBL‑E 
presence or absence in respiratory samples performed in ICU and to evaluate the impact of time sampling (≤5 days 
or >5 days) on such prediction. Design: Multicentric retrospective observational study, including every patient with 
a respiratory tract specimen positive culture and a previous rectal ESBL‑E screening performed within 7 days before 
the respiratory sample, between January 2012 and December 2014. Results were analyzed in two groups: respiratory 
samples obtained during the first 5 days of ICU stay (early group) and respiratory samples obtained after 5 days (late 
group). Interventions: none.
Results: Among 2498 respiratory tract samples analyzed corresponding to 1503 patients, 1557 (62.3%) were per‑
formed early (≤5 days) and 941 (37.7%) later (>5 days). Positivity rates for ESBL‑E were 15.0 and 36.8% for rectal swabs 
in the early and late groups, respectively. Sensitivity, specificity, positive (PPV) and negative (NPV) predictive values 
and likelihood ratios were calculated for ESBL‑E digestive colonization as a predictor of ESBL‑E presence in respira‑
tory samples. PPVs of ESBL‑E digestive colonization were 14.5% (95% CI [12.8; 16.3]) and 34.4% (95% CI [31.4; 37.4]), for 
the early and late groups, respectively, whereas NPVs were 99.2% (95% CI [98.7; 99.6]) and 93.4% (95% CI [91.9; 95.0]), 
respectively.
Conclusions: Systematic surveillance of ESBL‑E digestive colonization may be useful to limit the use of carbapenems 
when pneumonia is suspected in ICU. When rectal swabs are negative, the risk of having ESBL‑E in respiratory samples 
is very low even after 5 days of ICU stay.
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Background
Community-acquired, hospital-acquired and ventila-
tor-associated pneumonia (VAP) are the most common 
infections in intensive care units (ICU). They are asso-
ciated with high morbidity and mortality rates [1, 2], 
particularly if the administration of appropriate antimi-
crobial therapy is delayed [3–6]. The choice of empirical 
antimicrobial therapy is a challenge since it can only be 
validated a posteriori when sample cultures and anti-
biotic susceptibility testing are known [7]. Because of 
frequent long hospital stays, complex underlying pathol-
ogies and previous antimicrobial exposure, pneumonia 
is often related to multidrug-resistant (MDR) pathogens, 
particularly extended-spectrum β-lactamase-producing 
Enterobacteriaceae (ESBL-E) [8, 9]. Incidence of ESBL-
E is increasing, 15% of patients admitted in ICU have 
an ESBL-E digestive colonization in a French study con-
ducted between 2010 and 2011 [10]. The use of local epi-
demiological data and individual patient risk factors leads 
to frequent empirical prescription of broad-spectrum 
antimicrobial therapy, including carbapenems [11–13], 
leading to the emergence of MDR pathogens [14], espe-
cially carbapenemase-producing Enterobacteriaceae [15].
To prevent the overuse of such broad-spectrum antimi-
crobial therapy, rapid susceptibility testing [16–18] and 
colonization monitoring [19–21] have been developed, 
aiming to administer adequate treatment as early as pos-
sible. We have previously shown that microbiological 
examination of upper airways samples at ICU admission 
predicts the microorganisms involved in VAP occurring 
in the early course of a patient’s ICU stay with a high 
specificity and likelihood ratio [22].
The objectives of this study were: (1) to test the perfor-
mance of digestive colonization surveillance as a predic-
tor of ESBL-E presence or absence in respiratory samples 
performed in ICU; (2) to evaluate the impact of time 
sampling (≤5 days or >5 days) on such prediction; (3) to 
verify the impact of a medical versus surgical population 
on the results. We hypothesized that a systematic detec-
tion of ESBL-E digestive colonization may help to limit 
the use of carbapenems.
Methods
Study design and inclusion criteria
From January 2012 to December 2014, a multicentric 
retrospective observational study was performed in two 
teaching hospitals’ adult ICUs in Paris: the 21-bed sur-
gical ICU at Lariboisière Hospital and the 24-bed medi-
cal ICU at Cochin Hospital. In each center, an infection 
prevention and control team ensured that appropriate 
infection prevention and management strategies were 
implemented, evaluated for effectiveness and modi-
fied it, in agreement with the national surveillance 
network coordinated by the RAISIN (Réseau d’Alerte 
d’Investigation et de Surveillance des Infections Nosoco-
miales). Since rectal swabs and respiratory samples were 
part of our daily practice and no intervention was tested, 
the Ethics Committee of French Society of Intensive Care 
(Société de Réanimation de Langue Française, CE SRLF 
15-30) approved the protocol and waived the require-
ment of written informed consent. Furthermore, a dec-
laration to the Commission Nationale de l’Informatique 
et des Libertés (CNIL) was done (declaration number: 
1880024).
During the study period, patients having a respiratory 
specimen with a positive culture of any bacteria, includ-
ing ESBL-E, were enrolled (see below for microbiologi-
cal criteria). Respiratory samples were performed only 
in case of VAP suspicion in the surgical ICU, whereas 
systematic endotracheal aspirate surveillance cultures 
[19] were performed in the medical ICU. Patients with 
no previous rectal swab available within 7  days before 
the respiratory sampling were excluded. When duplicate 
respiratory samples were obtained within 48 h and were 
positive with the same pathogen, only one of them was 
included. Early respiratory samples corresponded to sam-
ples obtained during the first 5 days of ICU stay, defining 
the “early group.” Late respiratory samples corresponded 
to samples performed after 5 days of ICU stay, defining 
the “late group.” Clinical characteristics were collected to 
describe the population: age, sex ratio, simplified acute 
physiology score II (SAPS II), ICU mortality rate, length 
of stay in ICU, duration of mechanical ventilation and 
main admission diagnosis.
Microbiology
The microbiological methods were similar in the two 
centers (same swab, same medium, same inoculum 
device and same antibiotic susceptibility testing).
Rectal ESBL‑E screening Rectal ESBL-E screening was 
routinely performed within the first 24 h after ICU admis-
sion and weekly thereafter. Rectal swabs were performed 
by nurses using ESwab® (COPAN Diagnostics, Italy). 
Transport medium was then inoculated using PREVI® 
Isola standardized inoculation system (BioMérieux, 
Marcy-L’Etoile, France) on selective chromogenic Chro-
mID® ESBL agar plates (BioMérieux, Marcy-L’Etoile, 
France). Growing colonies were identified after 24  h of 
37 °C aerobic conditions incubation using mass spectrom-
etry with MALDI™ Biotyper system (Bruker Daltonics, 
Germany). Antimicrobial susceptibility was tested by disk 
diffusion method with Mueller–Hinton agar plates (MH 
agar plates, BioMérieux, Marcy-L’Etoile, France) accord-
ing to the EUCAST (European Committee on Antimicro-
bial Susceptibility Testing) and CA-SFM (Antibiogram 
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Committee of the French Society of Microbiology) guide-
lines [23]. ESBL-E digestive colonization was defined by 
one or more ESBL-E strain isolated from a rectal swab.
Respiratory samples Respiratory samples were endotra-
cheal aspirates (Unomedical, ConvaTec, Deeside, United 
Kingdom), sputum samples obtained by expectoration 
after oral care with the assistance of a physiotherapist 
when necessary, protected distal sampling (Combicath, 
Plastimed, Le Plessis Bouchard, France) using a fiberoptic 
bronchoscope, and bronchoalveolar lavages (BAL) dur-
ing bronchoscopy by slowly injecting and retrieving from 
the lung area of interest 100 mL of isotonic saline. Sam-
ples were isolated on agar plates using routine methods 
according to the French Society of Microbiology guide-
lines [23]. Microbiological identification and antimi-
crobial susceptibility testing were obtained as described 
above. Respiratory sample was defined as positive when at 
least 103 colony-forming units (CFU)/mL were observed 
in protected distal sampling, 104 CFU/mL in BAL, 106 
(CFU)/mL in endotracheal aspirates and 107 CFU/mL 
in sputum cultures. Culture results with microbiological 
identification and resistance patterns were reported to the 
treating physicians within 2  days after sampling. Focus 
was made on presence or absence of ESBL-E in the respir-
atory sample and in the previous rectal swab, regardless of 
the Enterobacteriaceae species.
Statistical analysis
Quantitative variables were described using median 
(interquartile range) or mean (standard deviation) 
and categorical variables using number (percentage). 
Proportions were compared using the Chi-square test. 
Continuous variables were compared by the Student t 
test. Nonparametric variables were compared using the 
Mann–Whitney test. Sensitivity, specificity, positive pre-
dictive value (PPV), negative predictive value (NPV) and 
likelihood ratios (LR) were obtained by standard statisti-
cal methods. Prism Software® (GraphPad Software®, La 
Jolla, USA) was used for the statistical analysis.
Results
Population characteristics
Demographic data of all patients (n = 1503), medical ICU 
patients (n = 1147) and surgical ICU patients (n = 356) 
are described in Table 1. The two populations clearly dif-
fered, the medical ICU patients being older, more severe 
at admission, with a higher mortality rate and a shorter 
length of stay.
Respiratory samples
A total of 4038 respiratory samples were performed 
among which 3610 (89.4%) were culture-positive. Among 
them, 1112 respiratory samples were excluded: 947 sam-
ples with missing rectal swabs, and 165 duplicate sam-
ples for which only one sample was included. Finally, 
2498 respiratory samples were obtained on 1503 patients. 
These samples were divided in 1557 (62.3%) early sam-
ples (≤5  days) and 941 (37.7%) late samples (>5  days) 
(Fig. 1). A total of 2073 and 425 respiratory samples were, 
respectively, collected in medical ICU (Cochin Hospital) 
and in surgical ICU (Lariboisière Hospital). Early respira-
tory samples (≤5 days, n = 1557) were performed during 
mechanical ventilation in 79.6% of cases after a median 
Table 1 Demographic data
Data are expressed as absolute values (percentage), mean (standard deviation) or median (interquartile range)
ICU Intensive care unit, SAPS II Simplified Acute Physiology Score II, MV Mechanical ventilation
p statistical difference between patients from medical and surgical ICU
Variable All patients (n = 1503) Surgical ICU patients (n = 356) Medical ICU patients (n = 1147) p
Age, year 63 (±17) 59 (±17) 64 (±17) <0.0001
Gender, male n (%) 983 (65.4) 230 (64.6) 753 (65.6) 0.7179
SAPS II, points 55 (±20.8) 42.2 (±13.9) 59.5 (±21) <0.0001
ICU mortality, n (%) 328 (21.8) 57 (16.0) 271 (23.6) 0.0021
Days of ICUa hospitalization, n 8 (3–19) 15 (7–26) 7 (3–15) <0.0001
Patients under MV, n (%) 1264 (84.1) 326 (91.6) 938 (81.8) <0.0001
Days of MV, n 6 (2–13) 10 (4–19) 5 (2–10) <0.0001
Main admission diagnosis, n (%)
 Respiratory distress 501 (33.3) 74 (20.8) 427 (37.2) <0.0001
 Neurological failure 407 (27.1) 175 (49.2) 232 (20.2) <0.0001
 Cardiac arrest 196 (13.0) 1 (0.3) 195 (17.0) <0.0001
 Sepsis or septic shock 122 (8.1) 24 (6.7) 98 (8.6) 0.2767
 Other 277 (18.5) 82 (23.0) 195 (17.0) 0.0103
Page 4 of 8Carbonne et al. Ann. Intensive Care  (2017) 7:13 
delay of 1 (0–2) day of ICU stay. Late respiratory samples 
(>5  days, n  =  941) were performed during mechanical 
ventilation in 90.4% of patients after a median delay of 13 
(8–23) days of ICU stay. Respiratory samples techniques 
were endotracheal aspirates (n  =  2122, 85.0%), sputum 
cultures (n =  240, 9.6%), BAL (n =  77, 3.1%) and distal 
protected aspirates (n = 59, 2.3%).
Microbiological epidemiology
ESBL-E prevalence in rectal swabs and respiratory sam-
ples are described in Table 2.
In the early group, 15.0% of rectal swabs were positive 
for ESBL-E, and only 14.5% of them corresponded with a 
respiratory sample positive for ESBL-E. In the late group, 
36.8% of rectal swabs were positive for ESBL-E and 34.4% 
of them corresponded with a respiratory sample positive 
for ESBL-E. The prevalence of ESBL-E in rectal swabs 
and in respiratory samples was not statistically different 
between the two study centers (Additional file 1: Table S1). 
Concerning the rectal swabs positive for ESBL-E, the main 
species identified were Escherichia coli (40.0%), Klebsiella 
pneumoniae (24.0%) and Enterobacter cloacae (18.1%). 
With the demographic data collected, we did not high-
light any risk factors of having a rectal swab positive for 
ESBL-E in both the early and late group (data not shown). 
Concerning the respiratory samples, Enterobacteriaceae 
represented the main species identified both in early and 
late group. The prevalence of ESBL-E in rectal swabs and 
in respiratory samples increased significantly in the late 
group compared to the early group (p < 0.0001). Figure 2 
depicts the evolution of proportion of ESBL-E positive rec-
tal swabs and respiratory samples with ICU length of stay. 
The proportion of ESBL-E positive respiratory samples 
increased versus time, when proportion of positive rectal 
swabs seemed stable until day 20, between 15 and 34%.
Performance characteristics of ESBL‑E digestive 
colonization as a predictor of ESBL‑E presence or 
absence in respiratory samples
Table 3 summarized the sensitivity, specificity, predictive 
values and likelihood ratios of ESBL-E digestive coloni-
zation as a predictor of ESBL-E presence or absence in 
respiratory samples performed early and late after ICU 
admission. For the early group, PPV for ESBL-E diges-
tive colonization was 14.5% (95% CI [12.8; 16.3]), and 
NPV was 99.2% (95% CI [98.7; 99.6]). For the late group, 
PPV for ESBL-E digestive colonization was 34.4% (95% 
CI [31.4; 37.4]), and NPV was 93.4% (95% CI [91.9; 95.0]). 
These results were not statistically different between the 
two study centers (Additional file 1: Table S2). With the 
data collected, we did not highlight any risk factors of 
having a respiratory sample positive for ESBL-E when the 
rectal swab was positive for ESBL-E (data not shown).
Fig. 1 Flowchart. ICU intensive care unit
Table 2 Extended‑spectrum β‑lactamase‑producing Enterobacteriaceae prevalence in rectal swabs and respiratory sam‑
ples in the early and late groups
Prevalence is expressed as absolute value (percentage). ESBL: extended-spectrum β-lactamase-producing Enterobacteriaceae. The early group is defined by respiratory 
samples collected within the first 5 days after intensive care unit (ICU) admission, and the late group is defined by respiratory samples collected after 5 days of ICU 
hospitalization
Early group (n = 1557) Respiratory sample ESBL-E (+)
45/1557 (2.9%)
Respiratory sample ESBL-E (−)
1512/1557 (97.1%)
Rectal swab ESBL‑E (+)
234/1557 (15.0%)
34 200
Rectal swab ESBL‑E (−)
1323/1557 (85.0%)
11 1312
Late group (n = 941) Respiratory sample ESBL-E (+)
158/941 (16.8%)
Respiratory sample ESBL-E (−)
783/941 (83.2%)
Rectal swab ESBL‑E (+)
346/941 (36.8%)
119 227
Rectal swab ESBL‑E (−)
595/941 (63.2%)
39 556
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Discussion
The appropriateness of empirical antimicrobial therapy 
for pneumonia is a critical issue in ICU. Current guide-
lines suggest to use local epidemiological data and 
individual patient’s risk factors to guide probabilistic 
antimicrobial therapy [11]. This may lead to the overuse 
of broad-spectrum antimicrobial therapy, particularly 
carbapenems. In the present study, we hypothesized that 
a systematic detection of ESBL-E digestive colonization 
may help to limit the use of carbapenems despite the 
high incidence of MDR pathogens risk factors in ICU. It 
is presumed that bacterial flora changes during ICU stay 
with colonization of the upper airway by digestive flora 
[24]. The performance of rectal swab to predict EBSL-
E presence or absence in respiratory samples was then 
investigated in early (≤5 days) and late (>5 days) period 
after ICU admission. Moreover, this approach could be 
pragmatic taking into account the evolution of inflamma-
tory patterns along time with an initial intense inflamma-
tory response that may result in organ dysfunction and 
early death, followed by a later phase characterized by a 
post-aggressive immunosuppression [25]. Medical and 
surgical ICU patients were investigated, insuring good 
external validity. The main results were: (1) Medical and 
surgical patients had similar prevalence of EBSL-E in rec-
tal swab and in respiratory samples, despite very differ-
ent clinical characteristics; (2) the early and late groups 
showed very different prevalence of EBSL-E in rectal 
swabs and respiratory samples; (3) when rectal swabs 
were negative, the risk of having ESBL-E in respiratory 
samples was very low for both early and late groups.
The prevalence of positive rectal swab was similar to 
the previously reported data, reaching 15.0% in rectal 
swabs performed before day 5 [10] and 36.8% in rectal 
swabs performed after day 5. This prevalence was higher 
than the one found by Bruyère et  al. (6.8%) in a study 
conducted in France between 2006 and 2013 [21].
Early after ICU admission (≤5  days), when the rectal 
swab was negative for ESBL-E, respiratory samples were 
also negative for ESBL-E in 99.2% of cases. This may help 
reduce the prescription of carbapenems when pneumo-
nia is suspected. When the rectal swab was positive for 
ESBL-E, only 14.5% of respiratory samples were positive 
for ESBL-E. As the patient may develop a pro-inflam-
matory response secondarily to pneumonia at the early 
phase of sepsis, the risk would be too high not to use car-
bapenems when the rectal swab is positive for ESBL-E 
and the clinical condition is severe. These patients might 
present a particular condition such as long-term hospi-
talization or iterative use of antimicrobial drugs selecting 
ESBL-E in their digestive flora. It would be interesting to 
identify risk factors of having a respiratory sample posi-
tive for ESBL-E when rectal swab is positive for ESBL-E 
in a patient cohort with pneumonia.
Late rectal swabs, performed after 5 days of ICU admis-
sion, showed a higher incidence of EBSL-E (36.8%) than 
early rectal swabs (15.0%). Among these samples, inter-
estingly the NPV remained very good (93.4%) despite 
the presence of several MDR pathogens risk factors since 
these patients are hospitalized in ICU for a median of 
13 days with a likely previous antimicrobial therapy. This 



































Fig. 2 Proportion of extended‑spectrum β‑lactamase‑producing 
Enterobacteriaceae among all rectal swabs and positive respiratory 
samples performed during 5 days periods. ESBL‑E extended‑spectrum 
β‑lactamase‑producing Enterobacteriaceae; ICU intensive care unit
Table 3 Sensitivity, specificity, positive predictive value, negative predictive value and likelihood ratios of digestive colo‑
nization for extended‑spectrum β‑lactamase‑producing Enterobacteriaceae in respiratory sample
LR likelihood ratio. Sensitivity, specificity, positive predictive value, negative predictive values are expressed as percentage [95% CI]. Likelihood ratios are expressed as 
absolute value [95% CI]
Variable Early group (≤5 days) (n = 1557) Late group (>5 days) (n = 941)
Sensitivity (%) [95% CI] 75.6% [73.4–77.7] 75.3% [72.6–78.1]
Specificity (%) [95% CI] 86.8% [85.1–88.5] 71.0% [68.1–73.9]
Positive predictive value (%) [95% CI] 14.5% [12.8–16.3] 34.4% [31.4–37.4]
Negative predictive value (%) [95% CI] 99.2% [98.7–99.6] 93.4% [91.9–95.0]
Positive LR [95% CI] 5.71 [4.63–7.05] 2.60 [2.26–2.99]
Negative LR [95% CI] 0.28 [0.17–0.47] 0.35 [0.26–0.46]
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when pneumonia is suspected. When the rectal swab was 
positive for ESBL-E, 34.4% of respiratory samples were 
also positive for ESBL-E, a relatively high incidence. Since 
these samples were related to the late phase of ICU stay, 
a sensible solution would be to wait for the microbiologi-
cal results before antimicrobial therapy initiation when 
the clinical condition is not life threatening. As a conse-
quence, overuse of carbapenems may be avoided in the 
late phase, with minimal individual risk and better con-
trol of MDR pathogens selection risk.
Relying on our results and on the American thoracic 
society guidelines [11], we suggest a decision tree for 
empirical antimicrobial therapy in patients with respira-
tory tract specimen positive culture and suspicion of 
pneumonia (Fig. 3).
One can argue that the very high NPV found in early 
(99.2% [98.7–99.6]) and late (93.4% [91.9–95.0]) groups 
were due to the low prevalence of ESBL-E in respira-
tory samples. However, in this study, the overall preva-
lence of ESBL-E in early and late respiratory samples was 
8.1% (203/2498), which was higher than the prevalence 
described in the French ICU nosocomial infection sur-
veillance network in 2013 (6.4%) and 2014 (4.9%) [26, 
27]. Consequently, our results can be generalized to ICUs 
with roughly the same ESBL-E prevalence in respiratory 
tract specimens’ cultures.
The link between rectal swabs and respiratory sam-
ples positive for EBSL-E is based on a debatable hypoth-
esis, suggesting a contamination from digestive flora 
to the respiratory tract [24]. The evolution of ESBL-E 
positive samples proportion versus duration of ICU stay 
revealed surprising results. From day 0 to day 20, the 
incidence of ESBL-E positive rectal swabs remained less 
than 35%, whereas the incidence of ESBL-E positive res-
piratory samples was increasing along time in a linear 
trend. This supports the idea of an increased respiratory 
colonization by EBSL-E from digestive flora. One can 
then hypothesize that the delay between the first ESBL-
E positive rectal swab and the respiratory sample might 
guide the decision to use carbapenems. If the first ESBL-
E positive rectal swab is early during the hospitalization, 
there might be a high risk to observe an EBSL-E positive 
Fig. 3 Suggestion of decision tree for empirical antimicrobial therapy in patients with respiratory tract specimen positive culture and suspicion of 
pneumonia. Suggestion of decision tree to limit the use of carbapenems in the setting of empirical antimicrobial therapy in patients with respira‑
tory tract specimen positive culture and suspicion of pneumonia. By “No Carbapenem,” the authors mean another empirical antimicrobial therapy 
based on local epidemiological data and the American Thoracic Society guidelines [11]. In the situation of an early positive respiratory tract speci‑
men culture with previous ESBL‑E positive rectal swab, the choice of empirical antimicrobial therapy should take into account patient’s severity and 
clinical condition. ICU intensive care unit, ESBL‑E extended‑spectrum β‑lactamase‑producing Enterobacteriaceae; PPV positive predictive value, NPV 
negative predictive value
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respiratory sample. On the contrary, if rectal swabs were 
negative for several days with a recent ESBL-E positive 
rectal swab, there might be a low risk of ESBL-E in the 
respiratory sample.
However, there are some limitations to our study. As 
high as 27% of the culture-positive samples have been 
excluded due to the absence of rectal swab. Moreover, 
the weight of patients who had multiple respiratory sam-
pling may have influenced the results. The evidence of a 
clinical benefit of ESBL-E digestive colonization surveil-
lance to predict the presence or the absence of ESBL-E 
in respiratory samples needs to be confirmed in a clini-
cal study involving pneumonia and not only respiratory 
samples. As we chose to focus on respiratory samples 
and not episodes of pneumonia, we did not study antimi-
crobial therapy regimens. We chose to focus on ESBL-E 
presence or absence in respiratory samples and in pre-
vious rectal swabs, regardless of the Enterobacteriaceae 
species. Indeed, the association of ESBL-E presence or 
absence in rectal swab and respiratory sample is relevant 
for the choice of empirical antimicrobial therapy, what-
ever the Enterobacteriaceae species. In addition, ESBL-E 
are transmitted through plasmids from an Enterobacte‑
riaceae strain to another, making the concordance inter-
pretation between respiratory and rectal ESBL-E difficult.
Conclusions
Systematic surveillance of ESBL-E digestive coloniza-
tion may be useful to limit the use of carbapenems when 
pneumonia is suspected, particularly in the late phase of 
ICU stay. When the rectal swab is negative for ESBL-E, 
whatever the length of stay in ICU, carbapenems may not 
be used. The evidence of clinical benefit of ESBL-E diges-
tive colonization surveillance to predict the presence or 
the absence of ESBL-E in respiratory samples needs to be 
confirmed in a large prospective clinical study.
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